US Stock MarketDetailed Quotes
IDXG Interpace Biosciences Inc
- 2.930
- -0.070-2.33%
15min DelayClose Oct 18 16:00 ET
12.82MMarket Cap16.28P/E (TTM)
3.000High2.680Low14.90KVolume2.900Open3.000Pre Close43.79KTurnover0.42%Turnover Ratio16.28P/E (Static)4.38MShares3.25052wk High-0.21P/B10.28MFloat Cap0.78052wk Low--Dividend TTM3.51MShs Float14200.000Historical High--Div YieldTTM10.67%Amplitude0.510Historical Low2.939Avg Price1Lot Size
Interpace Biosciences Inc Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 241.61%1.4M | -105.12%-58K | 149.26%3.79M | 513.04%1.14M | 134.06%1.11M | 114.08%411K | 190.35%1.13M | 11.78%-7.69M | 77.34%-276K | -379.88%-3.24M |
| Net income from continuing operations | 1,078.29%2.06M | 33.33%468K | 103.65%802K | 156.91%890K | 95.68%-614K | 104.44%175K | 115.62%351K | -46.95%-21.96M | 58.06%-1.56M | -298.99%-14.21M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 95.83%-3K |
| Depreciation and amortization | -66.78%188K | -67.81%160K | -54.28%1.6M | -50.08%647K | -117.17%-109K | -28.35%566K | -36.36%497K | -34.83%3.5M | 26.56%1.3M | -54.87%635K |
| Deferred tax | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -344.74%-93K | ---- | ---- |
| Other non cash items | -132.73%-72K | 793.75%143K | -26.85%839K | -112.54%-156K | 194.19%759K | 158.05%220K | -33.33%16K | 60.42%1.15M | 718.42%1.24M | -7.53%258K |
| Change In working capital | -20.65%-853K | -1,149.35%-808K | 97.92%-83K | 75.20%-370K | 133.89%917K | -351.60%-707K | 204.05%77K | -252.87%-3.99M | -208.12%-1.49M | -440.81%-2.71M |
| -Change in receivables | 55.69%-109K | -354.18%-1.14M | 136.84%49K | 36.25%-153K | 76.96%699K | -130.94%-246K | 76.82%-251K | -106.19%-133K | -166.67%-240K | -58.29%395K |
| -Change in payables and accrued expense | -306.06%-402K | --0 | 102.44%66K | 453.13%113K | 93.85%-190K | 84.48%-99K | -77.08%242K | 11.02%-2.71M | -103.87%-32K | -887.54%-3.09M |
| -Change in other current assets | -64.90%-343K | 220.56%343K | 51.10%-89K | -94.85%-265K | 146.79%277K | -133.02%-208K | 227.38%107K | -102.22%-182K | -140.36%-136K | -589.26%-592K |
| -Change in other current liabilities | 100.65%1K | 47.62%-11K | 88.77%-109K | 94.00%-65K | -77.49%131K | 69.57%-154K | -156.76%-21K | -551.68%-971K | -658.04%-1.08M | 1,392.31%582K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 241.61%1.4M | -105.12%-58K | 149.26%3.79M | 513.04%1.14M | 134.06%1.11M | 114.08%411K | 190.35%1.13M | 11.78%-7.69M | 77.34%-276K | -379.88%-3.24M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 13.60%-197K | 56.92%-28K | -101.40%-87K | 87.08%-142K | -95.29%348K | -240.30%-228K | -242.11%-65K | 2,070.16%6.21M | -578.40%-1.1M | 5,232.64%7.39M |
| Net PPE purchase and sale | -77.48%-197K | 56.92%-28K | -45.96%-470K | 27.55%-142K | -280.00%-152K | -65.67%-111K | -242.11%-65K | -2.22%-322K | -20.99%-196K | 72.22%-40K |
| Net business purchase and sale | ---- | ---- | -94.13%383K | 87.04%-117K | -91.70%617K | ---- | ---- | --6.53M | ---903K | --7.43M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 13.60%-197K | 56.92%-28K | -101.40%-87K | 87.08%-142K | -95.29%348K | -240.30%-228K | -242.11%-65K | 2,070.16%6.21M | -578.40%-1.1M | 5,232.64%7.39M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -185.71%-2M | -100.00%-600K | -267.73%-5.03M | -2,288.68%-2.53M | -3,291.49%-1.5M | -135.00%-700K | -128.33%-300K | -66.58%3M | -108.39%-106K | -77.51%47K |
| Net issuance payments of debt | -185.71%-2M | -100.00%-600K | -183.33%-2.5M | --0 | ---1.5M | -135.00%-700K | -130.00%-300K | -66.95%3M | --0 | --0 |
| Net common stock issuance | ---- | ---- | ---32K | 69.81%-32K | ---- | ---- | ---- | --0 | ---106K | -79.30%47K |
| Net other financing activities | ---- | ---- | ---2.5M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -185.71%-2M | -100.00%-600K | -267.73%-5.03M | -2,288.68%-2.53M | -3,291.49%-1.5M | -135.00%-700K | -128.33%-300K | -66.58%3M | -108.39%-106K | -77.51%47K |
| Net cash flow | ||||||||||
| Beginning cash position | -49.75%2.81M | -27.55%3.5M | 45.68%4.83M | -20.24%5.03M | 140.14%5.08M | 80.52%5.6M | 45.68%4.83M | -1.72%3.31M | 83.94%6.31M | -47.66%2.12M |
| Current changes in cash | -53.38%-793K | -189.32%-686K | -187.85%-1.33M | -3.58%-1.53M | -101.12%-47K | 47.51%-517K | 458.88%768K | 2,710.34%1.51M | -1,176.72%-1.48M | 786.42%4.19M |
| End cash Position | -60.25%2.02M | -49.75%2.81M | -27.55%3.5M | -27.55%3.5M | -20.24%5.03M | 140.14%5.08M | 80.52%5.6M | 45.68%4.83M | 45.68%4.83M | 83.94%6.31M |
| Free cash flow | 302.33%1.21M | -108.05%-86K | 141.42%3.32M | 311.44%998K | 129.02%953K | 110.05%300K | 183.90%1.07M | 11.67%-8.01M | 65.80%-472K | -300.49%-3.28M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
